|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Roche's third-quarter sales rose 6 percent, the world's biggest cancer drug maker said on Thursday, beating analyst forecasts thanks to better-than-expected revenue from its new multiple sclerosis medicine ...
Roche Holding AG’s top-selling drug Rituxan saw sales slide in Europe last quarter, hurt by competition from cheaper copycat medicines called biosimilars -- a harbinger of things to come for the aging ...
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.
ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.
Celgene became a biotech juggernaut thanks to a treatment for tricky blood cancers. Now drugs battling lupus, MS and more are on the stock’s potential hit list.
Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.
Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.
The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, Monsanto, Adaptimmune Therapeutics and Celgene
GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.
Bayer Aktiengesellschaft (BAYRY) inked a deal to sell selected Crop Science businesses to BASF for EUR 5.9 billion to as a part of its strategy to complete the planned acquisition of Monsanto Co.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Celgene Corp. Here are 5 ETFs with the largest exposure to CELG-US. Comparing the performance and risk of Celgene Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Celgene Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
Carter Worth, Cornerstone Macro, discusses how the health care sector is starting to heat up. The “Fast Money” traders weigh in.